September 17
- September 17
The MAFCA Annual Research Day brings together flow cytometry professionals for a full day of scientific presentations, research updates, and networking. The program features industry experts and multiple discussion tracks focused on the latest advancements, emerging research areas, and innovations in flow cytometry. Connect With Us at MAFCA…
October 1
- October 1
This workshop brings together industry experts and FDA perspectives to examine the key preclinical, bioanalytical, regulatory, and development considerations for successful IND filings for antibody-based therapeutics. Discussions will cover antibodies, antibody-drug conjugates, and multispecific antibodies, with topics ranging from pharmacology, PK/PD, bioanalysis, and toxicology to CMC activities, clinical development…
Blogs
Choosing between conventional and spectral flow cytometry and understanding exactly how the data travels from instrument to regulated reportable, has become one of the highest-leverage decisions in a biomarker program. The move to spectral flow is the most visible instrument shift of the past decade, but the harder…
Blogs
The companion animal health industry continues to experience significant growth as pet ownership rises, veterinary medicine advances, and owners increasingly seek innovative treatment options for their animals. Alongside this growth, sponsors developing pharmaceuticals, biologics, diagnostics, and other veterinary health products are navigating a rapidly evolving research environment. As…
Blogs
If an analyte is amenable to analysis, it’s difficult to ignore the benefits that LC-MS/MS can provide. There are numerous chaAntibody-drug conjugates (ADCs) have become one of the fastest growing classes of targeted therapeutics. By combining the specificity of monoclonal antibodies with highly potent cytotoxic payloads, ADCs are designed…
Posters & Papers
This paper, a collaboration between SCIEX and KCAS Bio, presents comprehensive LC-MS workflows for the quantitative analysis of antibody-drug conjugates (ADCs). Using trastuzumab deruxtecan as a model ADC, the study demonstrates sensitive quantification of free payload, total antibody, and conjugated ADC, highlighting the analytical performance and broad dynamic…
Blogs
Poster Title: Method Development and Validation for the Determination of Two Protein Biomarkers by Multiplexed Online and Offline Hybrid LC-MS/MS in Human Heart Tissue Can you explain your role at KCAS Bio? I am a Scientist 1 at KCAS Bio in the Mass Spectrometry Bioanalysis Method Development group. In…
Blogs
Receptor Occupancy (RO) assays by flow cytometry are a powerful tool for evaluating the extend of drug binding to its cell surface target, but they can also be challenging to design and execute well. Here’s a quick guide to the fundamentals, the common pitfalls, and what separates a strong study design from a risky one. What Is Receptor Occupancy? CAR-T therapies are living, and dynamic therapies; once…
October 19
- October 21
KCAS Bio at the World Vaccine Congress – Europe 2026 KCAS Bio is thrilled to announce our participation in the World Vaccine Congress Europe, taking place in Amsterdam, Netherlands, from October 19-21. This event gathers the world’s leading vaccine research, development, and manufacturing experts to share groundbreaking insights and…
October 13
- October 15
Join KCAS Bio at the 2026 Festival of Biologics, taking place from October 13-15 in Basel, Switzerland. This festival, hosted by Terrapinn, brings together global stakeholders across pharma, biotech, academia, regulation, and investment to explore the discovery, development, manufacturing and commercialization of biologic therapies. During presentations, panels, workshops,…
Blogs
How Context of Use and Fit for Purpose Validation Shape Biomarker Success – A CRO’s Perspective on Building Smarter Biomarker Strategies Every drug development program is built around a series of scientific questions. Has the drug reached its target? Is it producing the intended biological effect? Is the…
Podcasts
Episode #32 of The Conversational Flow explores several significant developments shaping the flow cytometry and biopharmaceutical industries, including advances in antibody drug conjugates (ADCs), questions surrounding circadian timing in cancer treatment, and major life sciences acquisitions. Our hosts, Brian and Adam, discuss how improvements in ADC linker technology and…